The HBA1 Knockout HEK293T Polyclonal Cells consist of a heterogeneous population of HEK293T cells with CRISPR/Cas9-mediated disruption of HBA1, encoding the alpha-globin subunit of hemoglobin. As a polyclonal knockout model, it offers a genetically diverse loss-of-function tool for studying alpha-globin functions without the bias of clonal selection.
Derived from the HEK293T line, these cells stably express the SV40 large T antigen, enabling high-level plasmid amplification and robust protein expression; they are widely used for viral packaging and functional genomics. The non-erythroid origin of HEK293T provides a clean background for examining alpha-globin roles distinct from erythroid-specific programs.
Alpha-globin, encoded by HBA1, is a hemoglobin subunit that transports oxygen in erythrocytes and acts as a nitric oxide (NO) dioxygenase in non-erythroid cells, modulating NO bioavailability and vascular tone. It interacts with alpha-hemoglobin stabilizing protein (AHSP) and endothelial nitric oxide synthase (eNOS), coupling oxygen sensing to NO scavenging. HBA1 transcription is regulated by HIF-1, GATA factors (GATA1), and NFE2, linking hypoxia, EPO, and KLF1-mediated pathways. The alpha-globin protein forms complexes with beta-globin and AHSP, and its interaction with eNOS modulates NO scavenging, influencing processes such as vasodilation and mitochondrial respiration.
Knockout of HBA1 in HEK293T cells removes alpha-globin, providing a system to examine its non-erythroid functions, particularly in NO metabolism and heme handling. By eliminating alpha-globin, researchers can dissect its regulation of eNOS activity, NO bioavailability, and downstream signaling in a kidney-derived context, free from erythroid-specific factors like GATA1. This model also permits studies of cellular adaptation to hypoxia, oxidative stress, and heme excess. The polyclonal nature ensures broad representation of knockout effects without clonal artifacts.
Typical research applications include investigating non-erythroid hemoglobin biology, delineating alpha-globin’s role in NO and heme networks, and screening drug candidates for alpha-thalassemia and Hemoglobin H disease. Compatible assays comprise Western blotting, RT-qPCR, flow cytometry, co-immunoprecipitation, RNA-seq, and functional measurements of NO, heme, and hypoxia-responsive genes. This polyclonal knockout model advances research into alpha-globin’s diverse biological roles. For inquiries, contact Ascent Research.
